Literature DB >> 23809661

Erectile dysfunction, penile atherosclerosis, and coronary artery vasculopathy in heart transplant recipients.

Nicola Caretta1, Giuseppe Feltrin, Giuseppe Tarantini, Chiara D'Agostino, Francesco Tona, Mirko Schipilliti, Riccardo Selice, Nadia Minicuci, Gino Gerosa, Carlo Foresta.   

Abstract

INTRODUCTION: Vascular erectile dysfunction (ED) is the expression of a systemic vascular disease and in particular of endothelial dysfunction. Dysfunctional endothelium plays also a significant role in the onset and progression of coronary artery vasculopathy (CAV). AIM: This pilot study was designed to evaluate the prevalence and pathogenesis of ED and its correlation with CAV in heart transplanted male.
METHODS: A total of 77 male heart transplanted patients (HTx) evaluated in our center (mean age 61.6 + 10.6 years) were enrolled in the study. MAIN OUTCOME MEASURES: All subjects underwent accurate medical history collection, including lifestyle (cigarette smoking, dietary and sedentary habits, drug intake, and erectile function before cardiac transplantation), physical examination (body mass index and arterial pressure), biochemical blood tests (fasting glucose, total cholesterol, high-density lipoprotein cholesterol, and triglycerides), and hormones (prolactin, luteinizing hormone and total testosterone). Furthermore, they were studied with penile, carotid, femoral echo-color Doppler ultrasonography and coronary angiogram.
RESULTS: Incidence of ED was 24% before HTx and increased up to 65% after. Postischemic cardiomiopathy was an indication to HTx in ED group more frequently than in patients without ED (No-ED group) (45.1% vs. 20%). ED patients showed a lower peak systolic velocity, a higher cavernosal intima-media thickness (IMT), a higher prevalence of cavernosal plaques (26.7% vs. 5.2%, P < 0.05), peripheral vascular disease (60.87% vs. 26.1%, P < 0.05) and CAV (45.8% vs. 25.8%, P < 0.05) with respect to No-ED patients. Coronary flow reserve was significantly reduced in ED vs. No-ED patients (2.43 + 0.7 vs. 2.9 + 0.8, P < 0.04). Finally, cavernous plaque and testosterone plasma levels were statistically associated with CAV.
CONCLUSIONS: We showed that ED is a frequent disease in HTx patients, more common when the original pathology is postischemic cardiomiopathy and associated with higher prevalence of cavernous plaques and CAV. Its evaluation should be integral to an HTx rehab program.
© 2013 International Society for Sexual Medicine.

Entities:  

Keywords:  Coronary Artery Vasculopathy; Endothelial Dysfunction; Erectile Dysfunction; Heart Transplant

Mesh:

Substances:

Year:  2013        PMID: 23809661     DOI: 10.1111/jsm.12233

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  4 in total

1.  SIAMS survey on sexological screening during the assisted reproductive technologies in Italy.

Authors:  G Ciocca; E Limoncin; D Mollaioli; G L Gravina; E Carosa; S Di Sante; D Gianfrilli; F Lombardo; A Lenzi; E A Jannini
Journal:  J Endocrinol Invest       Date:  2015-04-18       Impact factor: 4.256

Review 2.  Penile Doppler ultrasound predicting cardiovascular disease in men with erectile dysfunction.

Authors:  Nikhil Gupta; Amin Herati; Bruce R Gilbert
Journal:  Curr Urol Rep       Date:  2015-03       Impact factor: 3.092

Review 3.  Coronary Microvascular Function and Beyond: The Crosstalk between Hormones, Cytokines, and Neurotransmitters.

Authors:  Carlo Dal Lin; Francesco Tona; Elena Osto
Journal:  Int J Endocrinol       Date:  2015-06-01       Impact factor: 3.257

4.  Selective arterial embolization for uncontrollable urethral hemorrhage in a patient with a left ventricular assist device.

Authors:  Yujiro Hayashi; Atsunari Kawashima; Kazutoshi Fujita; Taigo Kato; Toyofumi Abe; Takeshi Ujike; Akira Nagahara; Shinichiro Fukuhara; Motohide Uemura; Hiroshi Kiuchi; Ryoichi Imamura; Tetsuya Saito; Koichi Toda; Yoshiki Sawa; Kentaro Kishimoto; Keigo Osuga; Norio Nonomura
Journal:  Urol Case Rep       Date:  2018-01-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.